Redirecting an Anticancer to an Antibacterial Hit Against Methicillin-Resistant Staphylococcus aureus

YM155 is a clinically evaluated anticancer with a fused naphthoquinone-imidazolium scaffold. In this study, we demonstrated that based on weak or cryptic antibacterial activity of YM155 against methicillin-resistant Staphylococcus aureus (MRSA) (MIC of 50 μg/ml), some congeneric compounds with short...

Descripción completa

Detalles Bibliográficos
Autores principales: Jang, Hye-Jeong, Chung, In-Young, Lim, Changjin, Chung, Sungkyun, Kim, Bi-o, Kim, Eun Sook, Kim, Seok-Ho, Cho, You-Hee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Microbiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6398426/
https://www.ncbi.nlm.nih.gov/pubmed/30858845
http://dx.doi.org/10.3389/fmicb.2019.00350

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6398426/
https://www.ncbi.nlm.nih.gov/pubmed/30858845
http://dx.doi.org/10.3389/fmicb.2019.00350

Ejemplares similares